59.99
Schlusskurs vom Vortag:
$59.02
Offen:
$59.35
24-Stunden-Volumen:
1.09M
Relative Volume:
0.43
Marktkapitalisierung:
$7.39B
Einnahmen:
$947.36M
Nettoeinkommen (Verlust:
$392.47M
KGV:
19.86
EPS:
3.02
Netto-Cashflow:
$392.71M
1W Leistung:
+3.91%
1M Leistung:
+11.09%
6M Leistung:
+5.67%
1J Leistung:
+10.91%
Halozyme Therapeutics Inc Stock (HALO) Company Profile
Firmenname
Halozyme Therapeutics Inc
Sektor
Branche
Telefon
(858) 794-8889
Adresse
12390 EL CAMINO REAL, SAN DIEGO, CA
Vergleichen Sie HALO mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
HALO
Halozyme Therapeutics Inc
|
59.99 | 7.27B | 947.36M | 392.47M | 392.71M | 3.02 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 118.67B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
571.54 | 59.23B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
419.56 | 52.67B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
690.32 | 41.24B | 3.05B | 1.28B | -614.78M | 19.58 |
![]()
ONC
Beone Medicines Ltd Adr
|
304.30 | 32.36B | 3.81B | -644.79M | -669.77M | -6.24 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-07-10 | Fortgesetzt | Goldman | Neutral |
2025-05-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2025-05-13 | Herabstufung | Leerink Partners | Market Perform → Underperform |
2024-10-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
2024-09-19 | Herabstufung | JP Morgan | Overweight → Neutral |
2024-06-07 | Herabstufung | Piper Sandler | Overweight → Neutral |
2024-02-29 | Eingeleitet | TD Cowen | Outperform |
2023-07-24 | Herabstufung | Goldman | Buy → Neutral |
2023-07-24 | Eingeleitet | H.C. Wainwright | Buy |
2023-05-10 | Hochstufung | Piper Sandler | Neutral → Overweight |
2023-03-27 | Fortgesetzt | Berenberg | Buy |
2023-03-16 | Herabstufung | SVB Securities | Outperform → Market Perform |
2022-12-21 | Fortgesetzt | Morgan Stanley | Overweight |
2022-11-28 | Eingeleitet | Wells Fargo | Overweight |
2022-09-09 | Eingeleitet | Morgan Stanley | Overweight |
2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
2021-06-14 | Eingeleitet | Evercore ISI | Outperform |
2021-05-17 | Eingeleitet | SVB Leerink | Outperform |
2021-05-11 | Herabstufung | Piper Sandler | Overweight → Neutral |
2021-01-21 | Bestätigt | The Benchmark Company | Buy |
2020-12-17 | Eingeleitet | Berenberg | Buy |
2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
2020-07-01 | Eingeleitet | The Benchmark Company | Buy |
2020-02-05 | Hochstufung | Piper Sandler | Neutral → Overweight |
2020-01-09 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
2020-01-08 | Eingeleitet | Goldman | Buy |
2019-11-05 | Hochstufung | Barclays | Underweight → Equal Weight |
2018-10-19 | Fortgesetzt | Piper Jaffray | Neutral |
2018-05-11 | Herabstufung | Barclays | Equal Weight → Underweight |
2018-01-24 | Eingeleitet | Goldman | Neutral |
2017-10-16 | Bestätigt | Piper Jaffray | Overweight |
2017-01-06 | Herabstufung | Citigroup | Buy → Neutral |
2016-11-03 | Eingeleitet | Deutsche Bank | Buy |
2015-12-04 | Eingeleitet | Wells Fargo | Outperform |
2015-11-18 | Eingeleitet | Citigroup | Buy |
2015-09-22 | Eingeleitet | Barclays | Overweight |
2015-06-22 | Bestätigt | JP Morgan | Overweight |
2015-03-03 | Bestätigt | UBS | Buy |
2015-02-18 | Bestätigt | MLV & Co | Buy |
2015-01-08 | Bestätigt | MLV & Co | Buy |
Alle ansehen
Halozyme Therapeutics Inc Aktie (HALO) Neueste Nachrichten
Earnings Outlook For Halozyme Therapeutics - 富途牛牛
What makes Halozyme Therapeutics Inc. stock price move sharplyMarket-beating returns - Jammu Links News
Halozyme Therapeutics Inc. Stock Analysis and ForecastTremendous growth potential - Jammu Links News
Does Halozyme Therapeutics Inc. stock perform well during market downturnsBuild a portfolio that withstands market volatility - Jammu Links News
What catalysts could drive Halozyme Therapeutics Inc. stock higher in 2025Fastest-growing stock picks - Jammu Links News
What analysts say about Halozyme Therapeutics Inc. stockDiscover stock picks with superior returns - Jammu Links News
What institutional investors are buying Halozyme Therapeutics Inc. stockDiscover market opportunities with real-time data - Jammu Links News
Is Halozyme Therapeutics Inc. stock overvalued or undervaluedExceptional growth trajectory - Jammu Links News
How many analysts rate Halozyme Therapeutics Inc. as a “Buy”Track top-performing stocks effortlessly - Jammu Links News
Alnylam, Halozyme among latest firms to win EU backing for drugs - MSN
Halozyme Therapeutics Insider Lowered Holding By 38% During Last Year - 富途牛牛
Morgan Stanley Maintains a Hold on Halozyme Therapeutics (HALO) With a $62 PT - MSN
A Quick Look at Today's Ratings for Halozyme Therapeutics(HALO.US), With a Forecast Between $47 to $79 - 富途牛牛
How Halozyme Therapeutics Inc. stock performs during market volatilitySmart Money Tracking Signal Generator Activated - metal.it
Short Interest Drops in Halozyme Therapeutics Inc. After RallyOversold Recovery Opportunity Stocks Attract Buyers - metal.it
Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Halozyme Therapeutics Inc. Outperforms Peers on Volume MetricsPrice Action Based Buy Opportunity List Published - metal.it
Why Halozyme Therapeutics Inc. stock attracts strong analyst attentionProfit Target Stock Opportunity Monitor Activated - metal.it
How Resilient Is Halozyme Therapeutics Inc. Stock During Economic DownturnsMarket Entry and Exit Point Tips From Traders - metal.it
Published on: 2025-07-28 01:53:45 - jammulinksnews.com
What is Halozyme Therapeutics Inc. company’s growth strategyOutstanding capital returns - Jammu Links News
Halozyme’s Promising Cancer Study: A Potential Game-Changer in Oncology - TipRanks
Should I buy Halozyme Therapeutics Inc. stock before earningsRecord-setting profit potential - jammulinksnews.com
What risks could impact Halozyme Therapeutics Inc. stock performanceConsistently superior profits - jammulinksnews.com
38% Of This Halozyme Therapeutics Insider's Holdings Were Sold - simplywall.st
Is Halozyme Therapeutics Inc. stock overhyped or has real potentialBreakout profit opportunities - jammulinksnews.com
Halozyme to Report Second Quarter 2025 Financial and Operating Results - Eastern Progress
BlackRock, Inc. Adjusts Holdings in Halozyme Therapeutics Inc. - GuruFocus
Halozyme Therapeutics Says Myeloma Drug With Enhanze Delivery Technology Gets EU Approval - 富途牛牛
Is Halozyme Therapeutics Inc. a good long term investmentFree Risk Assessment Services - jammulinksnews.com
J&J Darzalex injectable cleared in EU for smouldering MM (JNJ) - Seeking Alpha
Halozyme says EU approves new indication for Janssen’s Darzalex Faspro - TipRanks
European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma - WV News
What drives Halozyme Therapeutics Inc. stock priceFree Stock Market Real-Time Monitoring - jammulinksnews.com
Why Halozyme Therapeutics (HALO) is Poised to Beat Earnings Estimates Again - Yahoo Finance
Finanzdaten der Halozyme Therapeutics Inc-Aktie (HALO)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):